Notably, in the phase I trial (BLOOM), osimertinib revealed considerable treatment benefits in the CNS and a tolerable safety profile in patients with leptomeningeal metastases from EGFR-mutated advanced NSCLC [32]. Here, EGFR is linked to non-small cell lung carcinoma.